The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Open accessAbstract
Background Gene therapy with elivaldogene autotemcel (eli-cel) consisting of autologous CD34+ cells transduced with lentiviral vector containing ABCD1 complementary DNA (Lenti-D) has shown efficacy in clinical studies for the treatment of cerebral adrenoleukodystrophy. However, the risk of oncogenesis with eli-cel is unclear. Methods We performed integration-site analysis, genetic studies, flow cytometry, and morphologic studies in peripheral-blood and bone marrow samples from patients who received eli-cel therapy in two completed phase 2–3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304) involving the patients in both ALD-102 and ALD-104. Results Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel (1 of 32 patients in the ALD-102 study and 6 of 35 patients in the ALD-104 study): myelodysplastic syndrome (MDS) with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 patients at 28, 42, and 92 months; MDS in 1 patient at 36 months; and acute myeloid leukemia (AML) in 1 patient at 57 months. In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including at either MECOM–EVI1 (MDS and EVI1 complex protein EVI1 [ecotropic virus integration site 1], in 5 patients) or PRDM16 (positive regulatory domain zinc finger protein 16, in 1 patient). Several patients had cytopenias, and most had vector insertions in multiple genes within the same clone; 6 of the 7 patients also had somatic mutations ( KRAS , NRAS , WT1 , CDKN2A or CDKN2B , or RUNX1 ), and 1 of the 7 patients had monosomy 7. Of the 5 patients with MDS with excess blasts or MDS with unilineage dysplasia who underwent allogeneic hematopoietic stem-cell transplantation (HSCT), 4 patients remain free of MDS without recurrence of symptoms of cerebral adrenoleukodystrophy, and 1 patient died from presumed graft-versus-host disease 20 months after HSCT (49 months after receiving eli-cel). The patient with AML is alive and had full donor chimerism after HSCT; the patient with the most recent case of MDS is alive and awaiting HSCT. Conclusions Hematologic cancer developed in a subgroup of patients who were treated with eli-cel; the cases are associated with clonal vector insertions within oncogenes and clonal evolution with acquisition of somatic genetic defects. (Funded by Bluebird Bio; ALD-102, ALD-104, and LTF-304 ClinicalTrials.gov numbers, NCT01896102 , NCT03852498 , and NCT02698579 , respectively.)
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
In two completed phase 2–3 studies and long-term follow-up, 7 of 67 patients treated with elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy developed hematologic cancer, associated with clonal lentiviral vector insertions in MECOM or PRDM16 and acquired somatic defects. The authors conclude that this oncogenic risk must be weighed against the severity of cerebral adrenoleukodystrophy and that monitoring and future vector design should be informed by these cases.
Key findings
- Hematologic cancer developed in 7 of 67 eli-cel recipients (10%) over 338 person-years: incidence rate 2.1 per 100 person-years (95% CI, 0.8 to 4.2); 1 of 32 patients in ALD-102 (0.5 per 100 person-years; 95% CI, 0 to 2.5) and 6 of 35 in ALD-104 (5.2 per 100 person-years; 95% CI, 1.9 to 10.9).
- Diagnoses were MDS with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 at 28, 42, and 92 months; MDS in 1 at 36 months; and AML in 1 at 57 months.
- In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including MECOM–EVI1 in 5 patients and PRDM16 in 1; 6 of 7 patients also had somatic mutations (KRAS, NRAS, WT1, CDKN2A or CDKN2B, or RUNX1), and 1 of 7 had monosomy 7.
- Of 5 patients with MDS who underwent allogeneic HSCT, 4 remain free of MDS without recurrence of cerebral adrenoleukodystrophy symptoms, and 1 died from presumed graft-versus-host disease 20 months after HSCT (49 months after eli-cel); the AML patient is alive with full donor chimerism, and the most recent MDS patient is alive awaiting HSCT.
Methods
- Integration-site analysis, genetic studies, flow cytometry, and morphologic studies were performed on peripheral-blood and bone marrow samples from patients who received eli-cel in two completed phase 2–3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304).
- A total of 67 patients received eli-cel infusion (32 in ALD-102 and 35 in ALD-104); analyses included integration-site analysis, vector copy number, targeted sequencing with the Rapid Heme Panel, gene expression studies, chromosome analysis, fluorescence in situ hybridization, and flow cytometry.
- The main analysis characterized clinicopathological and genetic features of hematologic cancer cases as of April 25, 2024, with incidence rates and event-free survival reported.
Limitations
- The paper states that whether differences in mobilization and chemotherapy regimens played a role remains unclear, that additional unknown factors appeared to play a role in cancer development, and that persistent oligoclonality testing was not reliably predictive of transformation.
- The paper states that ongoing follow-up is critical to understanding longer-term safety and efficacy.
- Evident from the text: only 7 cancer cases were available, there was no randomized comparator, follow-up duration differed between ALD-102 and ALD-104, the seventh case had limited available data and was undergoing more-detailed investigation, and incidence estimates had wide confidence intervals.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
42 Own result · 7 Check pending · 7 Own interpretation · 3 No full text of the sources · 1 Not checked yet
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel”
- Also stated in: § PATIENTS · plain
“Hematologic cancer developed in 7 patients (incidence rate, 2.1 per 100 person-years [95% CI, 0.8 to 4.2]; 338 person-years of total follow-up)”
- Also stated in: § DISCUSSION · plain
“among the 67 patients treated with eli-cel, 7 patients (10%) have received a diagnosis of hematologic cancer”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > Abstract > RESULTS
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of April 25, 2024, the probability of event-free survival (survival without major functional disabilities, hematologic cancer, or rescue-cell administration or allogeneic hematopoietic stem-cell transplantation) at 4 years was 81.0% (95% confidence interval [CI], 68.8 to 88.8)”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainn = 67- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All seven patients, as compared with 35% of patients without hematologic cancer, had current oligoclonality.”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > INTEGRATION-SITE ANALYSIS AND CLONAL ANALYSES
plainstates an associationn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“1 who had been treated in the ALD-102 study (incidence rate, 0.5 per 100 person-years [95% CI, 0 to 2.5]; 222 person-years of follow-up)”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematologic cancer developed in 7 patients (incidence rate, 2.1 per 100 person-years [95% CI, 0.8 to 4.2]; 338 person-years of total follow-up)”
- Also stated in: § DISCUSSION · plain
“incidence rate, 2.1 per 100 person-years; 95% CI, 0.8 to 4.2”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
- Probably not a substantial claim. 1
- It may state two separate claims as one. 21
Create a free account to see these claims.
Create a free account to see these assumptions.
34 more claims
Create a free account to see all 60 claims and to verify the 11 references still open.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As reported by Duncan et al., in ALD-104, six cases of hematologic cancer have been recorded in either the 24-month or the long-term follow-up study (five cases of MDS and one case of acute myeloid leukemia).”
From Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy (2024) · cites this paper as [20]
In the citing paper
“On the other hand, it is useful to note that no other studies using LVVs across multiple disease applications have to date reported mutagenic events and that none of these have used LTR regulatory sequences to regulate transgene expression, rather using cellular or derivative cellular elements.59”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [59]
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C. C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Serio, C. D., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 711
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Self-citationClonal analysis of lineage fate in native haematopoiesis
Rodriguez-Fraticelli, A. E., Wolock, S. L., Weinreb, C. S., Panero, R., Patel, S. H., Jankovic, M., Sun, J., Calogero, R. A., Klein, A. M., & Camargo, F. D. (2018) · Nature · doi:10.1038/nature25168 · Cited by 596
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
Research works printed but not linked: 1
- Raymond GV Moser AB Fatemi A. X-linked adrenoleukodystrophy. In: Adam MP Feldman J Mirzaa GM et al. eds. GeneReviews. Seattle: University of Washington 1993 (http://www.ncbi.nlm.nih.gov/books/NBK1315/).
Cited by
The clinical landscape of CAR NK cells
Jørgensen, L. V., Christensen, E. B., Barnkob, M. B., & Barington, T. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00633-8 · Cited by 156
Viral and non-viral vectors in gene therapy: current state and clinical perspectives
Geng, G., Xu, Y., Hu, Z., Wang, H., Chen, X., Yuan, W., & Shu, Y. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105834 · Cited by 140
Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Eichler, F., Duncan, C. N., Musolino, P. L., Lund, T. C., Gupta, A. O., De Oliveira, S., Thrasher, A. J., Aubourg, P., Kühl, J.-S., Loes, D. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400442 · Cited by 107
Self-citationGreco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 72
Ottaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 46
Gene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 43
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 42
Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy
Fumagalli, F., Calbi, V., Gallo, V., Zambon, A. A., Recupero, S. M., Ciotti, F., Sarzana, M., Fraschini, M., Scarparo, S., Mattia, F. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2405727 · Cited by 42
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
Hu, J., & Dunbar, C. E. (2024) · Blood · doi:10.1182/blood.2024025828 · Cited by 37
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 34
Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery
Ahrens‐Nicklas, R. C., Kotch, C., Roche, A. M., Everett, J. K., Reddy, S., Santi, M., Madsen, P. J., Martos-Rus, C., Yrigollen, C. M., Small, J. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601608 · Cited by 33
Clinical hematopoietic stem cell-based gene therapy
John, T. D., & Czechowicz, A. D. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.029 · Cited by 30
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 28
Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review
Bai, Y., Cui, L., Liu, T., Wang, Z., Cao, H., He, S., Qiu, J., Li, Y., Zhou, Y., Shi, J., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00385 · Cited by 25
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
Booth, C., Masiuk, K. E., Vazouras, K., Fernandes, A. O., Xu‐Bayford, J., Fernandez, B. C., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502754 · Cited by 22
Gene therapy for β-thalassemia: current and future options
Hardouin, G., Miccio, A., & Brusson, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.001 · Cited by 20
Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.028 · Cited by 18
Flory, A. R., Lazzarotto, C. R., Li, Y., Chyr, J., Yang, M., Katta, V., Urbina, E., Lee, G., Wood, R. K., Matsubara, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637517 · Cited by 17
Chemical strategies for brain delivery of genomic therapy
Li, H., Yu, C., Markovic, T., Nestler, E. J., & Dong, Y. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00770-y · Cited by 16
Monitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 15
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells
Baker, D., Levine, B. L., & June, C. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00039-x · Cited by 14
Clinical perspective: Advancing hemophilia treatment through gene therapy approaches
Thornburg, C. D., PIPE, S. W., Cantore, A., Unzu, C., Jones, M., & Miesbach, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.023 · Cited by 13
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping
Jargalsaikhan, B.-E., Muto, M., & Ema, M. (2025) · Viruses · doi:10.3390/v17081036 · Cited by 13
Treatment of leukodystrophies: Advances and challenges.
Wolf, N. I., van der Knaap, M. S., & Engelen, M. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.03.016 · Cited by 11
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Self-citationPuig-Serra, P., Hinckley-Boned, A., Tristán‐Manzano, M., Río, P., Torres-Ruiz, R., Rodríguez, S., & Martín, F. (2025) · Human Gene Therapy · doi:10.1177/10430342251372474 · Cited by 11
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Fleming, T. J., Antoszewski, M., Lambo, S., Gundry, M. C., Piussi, R., Wahlster, L., Shah, S. B., Reed, F. E., Dong, K. D., Paulo, J. A., et al. (2025) · Blood · doi:10.1182/blood.2025028954 · Cited by 11
Large-scale discovery of potent, compact and erythroid specific enhancers for gene therapy vectors
Psatha, N., Sova, P., Georgolopoulos, G., Paschoudi, K., Iwata, M., Bloom, J. E., Ulyanova, T., Wang, H., Kirtsou, A., Vasiloudis, N.-I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59235-x · Cited by 10
Kok, N., Özkazanç, D., van Vliet, A. A., Steenmans, D., Singh, S. P., Sütlü, T., Georgoudaki, A., Raimo, M., Spanholtz, J., & Duru, A. D. (2025) · iScience · doi:10.1016/j.isci.2025.112548 · Cited by 8
Blood Biomarkers Reflecting Brain Pathology—From Common Grounds to Rare Frontiers
Weinhofer, I., Rommer, P. S., & Berger, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70032 · Cited by 8
Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Dunbar, C. E. (2024) · New England Journal of Medicine · doi:10.1056/nejme2409399 · Cited by 8
He, H., He, Z., Lund, S. P., Turner, L., Fan, Y., Qiu, Y. F., Corney, D. C., Dropulić, B., Orentas, R. J., Slessareva, O., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101472 · Cited by 7
Stem cell and gene therapies for leukodystrophies
Lin, W., Zhang, M., Zheng, S., & Lian, Q. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101527 · Cited by 7
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 7
Rist, M., Kaku, M., & Coffin, J. M. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013087 · Cited by 7
Myelodysplasia after Lentiviral Gene Therapy
Kohn, D. B., Booth, C., & Naldini, L. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2414069 · Cited by 7
Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy
Huang, J. Y., Freed, B., Hanus, M., Keefe, K., Chiang, M. S. R., Brezzani, A., Luo, Y., Li, Y., Lam, B., Holley, S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113248 · Cited by 6
Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells
Petrova, I. O., & Smirnikhina, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311466 · Cited by 6
The Newborn Screening Programme Revisited: An Expert Opinion on the Challenges of Rett Syndrome
Singh, J., & Santosh, P. (2024) · Genes · doi:10.3390/genes15121570 · Cited by 6
CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype
Herreño-Pachón, A. M., Leal, A. F., Khan, S. A., Alméciga-Díaz, C. J., & Tomatsu, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094334 · Cited by 6
Opportunities and Challenges of Fetal Gene Therapy
Jeanne, M., & Chung, W. K. (2025) · Prenatal Diagnosis · doi:10.1002/pd.6809 · Cited by 6
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development
Fang, E., He, G., Chang, Y., He, Q., Chen, P., & Hu, K. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01472-y · Cited by 6
Shen, J., Wang, Y., Liu, Y., Lan, J., Long, S., Li, Y., Chen, D., Yu, P., Zhao, J., Wang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202415224 · Cited by 6
Çelik, B., Rintz, E., Khan, S. A., Leal, A. F., Nidhi, F., & Tomatsu, S. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101514 · Cited by 5
Albert, M. H., Lankester, A. C., Wynn, R. F., Gennery, A. R., Hoenig, M., Kreins, A. Y., Morris, E. C., Slatter, M. A., Bernardo, M. E., Neven, B., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02906-0 · Cited by 5
Could Lentivirus Overcome the AAV Gene-Therapy Challenges in Hemophilia A?
Mahlangu, J. N. (2024) · New England Journal of Medicine · doi:10.1056/nejme2414214 · Cited by 5
The future of ex vivo hematopoietic stem cell gene editing: what’s next
Cavazza, A., & Santilli, G. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2480003 · Cited by 5
Bastone, A. L., John-Neek, P., Dziadek, V., Mansel, F., Hagedorn, M., Fleischauer, J., Weigel, B., Paul, G., Schambach, A., & Rothe, M. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.221 · Cited by 4
Non-viral vectors as beacons of hope for reducing genotoxic risks of gene therapy
Nzila, M.-M., Koehl, U., & Ivics, Z. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01581-8 · Cited by 4
Futuristic global cell and gene therapy regulations based on a review of today’s leading frameworks
Hashmi, S. K., Jamil, M. A., de la Fuente, J., Mahlangu, J. N., Ozelo, M. C., Walters, M. C., Mannaei, A. I. A., Srivastava, A., Alzahrani, H. A., Lu, P., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102064 · Cited by 4
Laugwitz, L., Fumagalli, F., Wehner, K., Martin, P., Kern, J. M., Kaiser, N., Kehrer, C., Launer, T., Juengling, P., Steiner-Wilke, I., et al. (2026) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2026.06.004 · Cited by 4
Hosuru, R. V., Yang, J., Zhou, Y.-F., Gin, A. L., Hayal, T. B., Hong, S. G., Dunbar, C. E., & Wu, C. (2024) · British Journal of Haematology · doi:10.1111/bjh.19889 · Cited by 4
Mayer-Hamblett, N., Kerper, N. R., Clancy, J. P., Davies, J. C., Taylor‐Cousar, J. L., Donaldson, S. H., Bell, S. C., Jain, R., Simmonds, N. J., Mall, M. A., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00206-1 · Cited by 4
Gene therapy for lysosomal storage diseases
Kobayashi, H. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104399 · Cited by 4
Recent advances and clinical prospects of non-viral brain-targeted gene delivery systems
Wang, S., Xu, L.-L., Ma, F., Xu, M., Chen, G., Wang, D., Wu, X., Wang, P., Yu, J., & Shi, L. (2025) · Applied Physics Reviews · doi:10.1063/5.0255745 · Cited by 4
Oligodendrocytes, the Forgotten Target of Gene Therapy
Ozgür-Gunes, Y., Stunff, C. L., & Bougneres, P. F. (2024) · Cells · doi:10.3390/cells13231973 · Cited by 4
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 4
Maurer, K., & Jacobson, C. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2460043 · Cited by 4
Suleman, S., Alhaque, S., Guo, A. Y., Zhang, H., Payne, A. M., Zahn, M., Fawaz, S., Khalifa, M. S., Jobling, S., Hay, D. C., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00550-9 · Cited by 4
Quezada‐Ramírez, M. A., Loncar, S., Campbell, M. A., Parsi, K. M., Gifford, R. J., & Kotin, R. M. (2025) · iScience · doi:10.1016/j.isci.2025.113910 · Cited by 4
Lorenzini, M. H., Balderson, B., Lavalle, S. N., Sajeev, K., Ho, A. J., Light, M., Usman, O. H., Kurgan, G., & McVicker, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.07.636966 · Cited by 4
From trial to transformation: insights into hematopoietic stem cell-gene therapy for Hurler syndrome
Tucci, F., Consiglieri, G., Cossutta, M., & Bernardo, M. E. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2606047 · Cited by 4
Patient-centered long-term follow-up for gene therapies aligns with ethics and science
Chapman, C. R., Cripe, T. P., & Bateman-House, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.040 · Cited by 3
Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases
Consiglieri, G., Tucci, F., & Bernardo, M. E. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104384 · Cited by 3
HIV-1 transcription dominates over host gene activity at the HIV-1 integration site
Weissman, S., Yeh, Y.-H. J., Viazmenski, M. R., Kim, R., Collora, J. A., Steinhauser, S. F., & Ho, Y. (2025) · mBio · doi:10.1128/mbio.02755-25 · Cited by 3
Nagy, A., Thompson, R., & Eichler, F. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.12.006 · Cited by 3
Self-citationAddressing the package: Cell-specific gene delivery using lentiviral vectors
As, S., Warnecke, F. L., Schott, J. J., Morgan, M., & Schambach, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.031 · Cited by 3
Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome
Ferrua, F., Cenciarelli, S., Giannelli, S., Galimberti, S., Chandrakasan, S., Fraschetta, F., Caputo, C., Sala, D., Monti, I., Barzaghi, F., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2515005 · Cited by 3
Rewriting the script: gene therapy and genome editing for von Willebrand Disease
Barraclough, A., Bär, I., van Duijl, T. T., Fijnvandraat, K., Eikenboom, J. C. J., Leebeek, F. W. G., Bierings, R., Voorberg, J., & Trasanidou, D. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1620438 · Cited by 3
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Sanal, M. G., & Jindal, A. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2502741 · Cited by 3
Yang, Z., Li, H., Luo, M., Yi, H., Han, X., Liu, E., Yao, S., & Hu, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136922 · Cited by 2
John, T. D., & Krishnamurti, L. (2025) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2025.08.018 · Cited by 2
Lentiviral hematopoietic stem cell gene therapy ameliorates GM1-gangliosidosis in mice
Bucciarelli, L., Fabris, C., Accardo, M., Biffi, A., & Poletti, V. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.007 · Cited by 2
Chen, Z., Wu, M., Wang, X., & Liang, W. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151033 · Cited by 2
Dib, C., Queenan, J. A., Willner, H., Swartzrock, L., Charlesworth, C. T., Denis, M., Davis, J. R., Mepani, R. J., Ho, K., Castro, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.010 · Cited by 2
Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
Cozmescu, A. C., Nazari, M., Touramanidou, L., Gurung, S., Perocheau, D. P. B., Sebire, N. J., Hu, Y., Goldsworthy, S., Burden, J. J., Khalil, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73631-x · Cited by 2
Blood Cancers Reported in Seven Children Dosed with SKYSONA™
Philippidis, A. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.89758.hgt · Cited by 2
Safety and efficacy of gene therapy for RAG1-deficient SCID
Staal, F. J. T., Pike‐Overzet, K., de Kivit, S., de Bruin, L. M. O., Mamede, L., Pergent, M., Prevot, J., Rothe, M., Schambach, A., & Lankester, A. C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.044 · Cited by 2
Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial
Niu, M., Guo, J., Yang, Y., Xu, Q., Cheng, C., Li, H., Luo, N., Zhou, H., Zhang, P., Li, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04436-0 · Cited by 2
Gene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism
Benedetti, D. J., Marron, J. M., & Kodish, E. D. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01844 · Cited by 2
Luna, S. E., Feist, W. N., Ben-Efraim, K., Pendergast, M. A., Ekman, F. K., Hernandez, B. N., Merritt-Garza, M. E., Romero, K., Kostamo, Z., Amorin, N. A., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201799 · Cited by 1
Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis
Yöder, M. C., & Sen, C. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.013 · Cited by 1
The development of an advanced lentiviral gene therapy for beta-thalassemia
Liu, H., Wang, Y., Zhang, R., & Chang, L. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152963 · Cited by 1
Chen, K., & Wang, S. (2025) · Biomedicines · doi:10.3390/biomedicines13122999 · Cited by 1
Canepari, C., Milani, M., Degl’Innocenti, S., Monti, M., Volpin, M., Starinieri, F., Cavallo, M., Fabiano, A., Biffi, M., Longo, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.036 · Cited by 1
Fleischauer, J., John-Neek, P., Ha, T.-C., Mansel, F., Kosanke, M., Selich, A., Hagedorn, M., Bastone, A. L., Schinke, M., Dziadek, V., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07700-6 · Cited by 1
Evidence of Iron Accumulation in Cerebral Adrenoleukodystrophy: A Potential Novel Disease Mechanism
Nemeth, C. L., Şişman, M., Zhang, J., Shin, H., Li, X., Turk, B. R., Fatemi, A. S., Nguyen, T., & Mallack, E. J. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70346 · Cited by 1
Dong, X., Sun, Y., Guo, Y. P., Wang, J., Wang, F., Wang, Z., Li, R., Xie, F., Tan, T., Cheng, B., et al. (2026) · MedComm · doi:10.1002/mco2.70702 · Cited by 1
Eapen, M., & Williams, D. A. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102906 · Cited by 1
Self-citationDong, R., Zhang, Y., Yuan, G., Yue, X., Ding, Y., Zeng, X., & Xiao, H. (2026) · Cancer Medicine · doi:10.1002/cam4.71918 · Cited by 1
Precision medicine in paediatrics: Progress and priorities
Husain, N., Booth, C., Standing, J. F., & Barker, C. I. S. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70573 · Cited by 1
Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression
Bandala‐Sanchez, E., Petley, E. V., Ramsay, K. A., Hilton, A. A., White, C. A., Bediaga, N. G., Suen, C. S. N. L. W., Naik, S. H., Davey, A. S., Call, M. E., et al. (2026) · Blood · doi:10.1182/blood.2026033156 · Cited by 1
Novel VSV-G Variants with Enhanced Blinding for Targeted Delivery of Lentiviral Vectors
Warnecke, F. L., Ertelt, M., As, S., Harre, J., Warnecke, A., Araujo, A. E., Büning, H., Morgan, M., Schoeder, C. T., Schott, J. W., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261466823 · Cited by 1
Unlocking the curative potential of gene transfer and editing for hematopoietic disorders
Shiroshita, K., Stolz, A., Malouf, C., Tran, V. L., Li, J., Weiss, M. J., & Naldini, L. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105493 · Cited by 1
Graham, J. P., Arteaga, A., Moghaddam, A. S., Spiller, K. L., Laverty, D. J., & Gonzalez‐Fernandez, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728905 · Cited by 1
494. Hematopoietic Stem Cell Gene Therapy for Cystinosis
(2013) · New England Journal of Medicine · doi:10.1016/s1525-0016(16)34829-8
Lega, S. (2024) · Medico e Bambino · doi:10.53126/meb43553
Benefits of Gene Therapy for Cerebral ALD Persist at 6 Years, but With Malignancy Risk
Shaw, G. (2024) · Neurology Today · doi:10.1097/01.wnt.0001095444.29034.a0
The FACTs trial for Fabry disease highlights the promise and challenges of gene therapy
Medin, J. A., & West, M. L. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70028
Perspektivy gennoj terapii gemopoeticheskimi stvolovymi kletkami
Valieva, Y., & POPOV, K. A. (2024) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2024.074
Metadata
- Authors
- Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., Prasad, V. K., Downey, G. F., Pierciey, F. J., Kinney, M. A., Foos, M., Lodaya, A., Floro, N., Parsons, G., Dietz, A. C., Gupta, A. O., Orchard, P. J., Thakar, H. L., & Williams, D. A.
- Affiliations
- Boston Children's Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-10
- Volume
- 391
- Issue
- 14
- Pages
- 1287-1301
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11846662
- OpenAlex
- W4403262140
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 76 · 2025: 72 · 2024: 15
- FWCI
- 32.80
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- Bluebird Bio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- cerebral adrenoleukodystrophy, gene therapy, hematologic malignancies, myelodysplastic syndrome, acute myeloid leukemia, EVI1, MECOM, PRDM16, somatic mutations, monosomy 7, allogeneic hematopoietic stem cell transplantation
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Adolescent, Adrenoleukodystrophy, Child, Female, Follow-Up Studies, Genetic Vectors, Humans, Male, Myelodysplastic Syndromes, Genetic Therapy, Lentivirus, Hematologic Neoplasms, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
